Abstract Details

Title Development of a Novel Clinical Trial Endpoint for Neurogenic Intermittent Claudication

Topic Neural Repair/Rehabilitation

Presentation(s) (-)

Poster/Presentation
Number 173

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
John Markman, MD, FAAN (Eli Lilly)	Dr. Markman has received personal compensation for serving as an employee of Eli LIlly.
	No disclosure on file
	No disclosure on file
Holly C. Rutherford, MD	No disclosure on file
	No disclosure on file
Kathleen Alwell	No disclosure on file

��ɫ����